MMAA: A Drug Target / Disease Biomarker (G166785)

Target Name: MMAA

NCBI ID: G166785

MMAA

MMAA: A Drug Target / Disease Biomarker

Multiple Myeloma (MM) is a type of cancer that affects the bone marrow, where blood cells are produced. It is a type of hematological malignancy that is characterized by the production of a single type of white blood cell called a myeloma cell, which is a type of plasma cell that is responsible for producing antibodies.MM is a serious and aggressive disease that can be difficult to treat, with treatment options limited to chemotherapy, radiation therapy, and targeted therapies.

One potential drug target for MM is the protein known as MMB-1 (Mesothelin-associated protein 1). MMB-1 is a transmembrane protein that is expressed in various tissues throughout the body, including the bone marrow, where it is thought to play a role in the regulation of bone marrow development and the production of blood cells.

Studies have shown that MMB-1 is highly expressed inMM cells, and that it is involved in the development and progression of the disease. Additionally, MMB-1 has been shown to be a potential drug target forMM by several researchers, with several studies suggesting that inhibiting MMB-1 activity could be an effective way to treat the disease.

One of the main reasons for the potential of MMB-1 as a drug target is its involvement in the regulation of cell growth and differentiation. MMB-1 has been shown to play a role in the regulation of cell cycle progression, and to influence the activity of several cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development of cancer.

Additionally, MMB-1 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This is thought to be a key factor in the development of MM, as the buildup of new blood vessels in the bone marrow is thought to contribute to the growth and progression of the disease.

Another potential mechanism by which MMB-1 may contribute to the development and progression of MM is its role in the regulation of immune cell function. MMB-1 has been shown to play a role in the regulation of immune cell function, and to influence the activity of T cells, which are a key component of the immune system.

Treatment of MM often involves a combination of chemotherapy, radiation therapy, and targeted therapies, which can be effective in controlling the symptoms of the disease and slowing its progression. However, these treatments can be difficult to tolerate, and the disease can continue to progress despite treatment.

In conclusion, MMB-1 is a potential drug target for MM, due to its involvement in the regulation of cell growth and differentiation, angiogenesis, and immune cell function. Further research is needed to fully understand the role of MMB-1 in the development and progression of MM, and to develop effective treatments.

Protein Name: Metabolism Of Cobalamin Associated A

Functions: GTPase, binds and hydrolyzes GTP (PubMed:28497574, PubMed:20876572, PubMed:21138732, PubMed:28943303). Involved in intracellular vitamin B12 metabolism, mediates the transport of cobalamin (Cbl) into mitochondria for the final steps of adenosylcobalamin (AdoCbl) synthesis (PubMed:28497574, PubMed:20876572). Functions as a G-protein chaperone that assists AdoCbl cofactor delivery from MMAB to the methylmalonyl-CoA mutase (MMUT) (PubMed:28497574, PubMed:20876572). Plays a dual role as both a protectase and a reactivase for MMUT (PubMed:21138732, PubMed:28943303). Protects MMUT from progressive inactivation by oxidation by decreasing the rate of the formation of the oxidized inactive cofactor hydroxocobalamin (OH2Cbl) (PubMed:21138732, PubMed:28943303). Additionally acts a reactivase by promoting the replacement of OH2Cbl by the active cofactor AdoCbl, restoring the activity of MMUT in the presence and hydrolysis of GTP (PubMed:21138732, PubMed:28943303)

The "MMAA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MMAA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets